Bigelow Investment Advisors LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 1.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,254 shares of the medical research company’s stock after selling 23 shares during the period. Bigelow Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,246,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the stock. Signature Resources Capital Management LLC raised its position in Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. LifeSteps Financial Inc. acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. New Millennium Group LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $29,000. Stephens Consulting LLC grew its stake in shares of Thermo Fisher Scientific by 116.0% in the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Finally, True Wealth Design LLC lifted its holdings in Thermo Fisher Scientific by 1,275.0% during the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after buying an additional 51 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, VP Lisa P. Britt sold 3,624 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the sale, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares of the company’s stock, valued at approximately $8,397,760.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,084 shares of company stock valued at $14,094,292. Insiders own 0.34% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Analysis on TMO
Thermo Fisher Scientific Stock Down 0.4 %
TMO stock opened at $611.17 on Friday. The stock’s 50 day moving average is $592.10 and its 200-day moving average is $580.06. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88. The firm has a market capitalization of $233.47 billion, a PE ratio of 39.20, a P/E/G ratio of 2.88 and a beta of 0.78. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same quarter in the prior year, the company posted $5.15 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Following Congress Stock Trades
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Dividend Capture Strategy: What You Need to Know
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.